February 27, 2024 7:30am

Trading sentiment seems skimpy; it’s about refining expectation and defining insight

Q4 and FY23 Earnings: Beam Therapeutics (BEAM) and Regenxbio (RGNX)

Pre-open Indications: 1 Sell into Strength, 2 Positive and 1 Negative Indications

Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading! Join me … in the NO spin zone and new website!

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi provides the extenuating factors of share pricing.

 

Tuesday: The pre-open Dow futures are UP +0.03% or (+12 points), the S&P futures are UP +0.14% or (+7 points) as the Nasdaq futures are UP +0.30% or (+54 points)

Stock futures seemed relatively flat on Tuesday.

European markets were mixed,

Asia-Pacific markets traded mixed

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Monday, indexes slipped retreating from a record notched last Friday as investors await key inflation data as the Dow closed DOWN -62.30 points or -0.16%, the S&P closed DOWN -190.27 points -0.38% while the Nasdaq closed DOWN -20.57 points or -0.13%.

Economic Data Docket: economic data on durable goods, housing and consumer confidence.

 

Monday’s night RegMed Investors (RMi) Closing Bell: “bubblicious sentiment? As a 4th positive close begets a bigger bubble. “ … https://www.regmedinvestors.com/articles/13345   

Q1/24: February – 1 market holiday, 10 positive and 7 negative closes

  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength:

Monday, Friday, Thursday, Wednesday and last Tuesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Blueprint Medicine (BPMC) closed up +$5.56 after Friday’s +$3.49, Thursday’s -$1.26, Wednesday’s -$3.99 and last Tuesday’s +$0.99 with a positive +$0.20 or +0.21% pre-open indication.

 

Negative Indications:

Monday, Friday, Thursday, Wednesday and last Tuesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Fate Therapeutics (FATE) closed down -$0.01 after Friday's +$0.08 with a neutral -$0.00 or 0.00% pre-open indication.

 

Positive indications:

Monday, Friday, Thursday, Wednesday and last Tuesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Vericel (VCEL +$0.76 after Friday’s $, Thursday’s +$0.18, Wednesday’s -$1.37 and last Tuesday’s +$0.30 with a positive +$0.91 or +1.89% pre-open indication

Beam Therapeutics (BEAM) closed up +$1.81 after Friday’s +$0.45, Thursday’s +$1.78 with a positive -+$0.70 or +1.96 pre-open indication. <earnings today>

 

The BOTTOM LINE: The cell and gene therapy sector equities had a strong session on Monday after Friday and Thursday after Wednesday’s weak yet, positive session after last Tuesday’s negative session.

  • The remainder of the month’s trading sessions will be critical as the RegMed sector continues earnings’ in LPS (loss-per-share) season, estimates and consensus which set market reaction and will report “runways” and those whose cash positions render their future questionable.

 

I have seen 1 net income for the Q4 (but a FY23 loss) – CRISPR Therapeutics (CRSP).

8 have reported … FATE, NTLA, CRSP, IONS, SAGE, RARE, BPMC and ALNY.

RegMed Investors (RMi) Research Note: Q4/23 earnings reporting dates, net losses, cash positions and runway outcomes … https://www.regmedinvestors.com/articles/13166

 

This week: Tuesday -RGNX and BEAM , Wednesday – MDXG, EDIT, VYGR and Thursday – BLFS and VCEL

 

I reiterate, “Don't chase the cell and gene therapy sector, especially with the Nasdaq extended.”

Short and non-sweet: SELL into STRENGTH – accumulate some “powder” i.e., cash!

<span style="font-family:&quot;rom Friday" s="" market:",serif'=""> 

<span style="font-family:&quot;rom Friday" s="" market:",serif'="">Quote to ponder: "It's a lot of position squaring ahead of the big (economic) data, investors are just trying to make sure they're not underweight or overweight since trends are not moving." <Rob Haworth, senior investment strategist at U.S. Bank Wealth Management in Seattle>

 

From Monday’s market:

  • U.S. stocks ended with modest losses on Monday
  • The Nasdaq saw a slim gain melt away as it finished the session down 0.1%.
  • Treasury yields moved higher. The 10-year Treasury note rose 2 basis points to 4.28% while the 30-year also inched up 2 basis points to 4.4%. The 5-year yield popped 3 basis points to 4.31% while the 2-year rose 4 basis points to 4.73%.

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.